Patient characteristics
| Category . | Total . | MICA-129 matched . | MICA-129 mismatched . | P value . |
|---|---|---|---|---|
| Age | .258 | |||
| Median | 54 | 54 | 53.5 | |
| Range | 18-76 | 18-76 | 18-75 | |
| Diagnosis | .777 | |||
| AML | 808 (37.2) | 757 (37.4) | 51 (34.9) | |
| MDS | 552 (25.4) | 511 (25.2) | 41 (28.1) | |
| NHL | 339 (15.6) | 314 (15.5) | 25 (17.1) | |
| ALL | 309 (14.2) | 288 (14.2) | 21 (14.4) | |
| Acute leukemia | 164 (7.6) | 156 (7.7) | 8 (5.5) | |
| Disease stage | .513 | |||
| Early | 958 (44.1) | 895 (44.2) | 63 (43.2) | |
| Intermediate | 630 (29.0) | 582 (28.7) | 48 (32.9) | |
| Advanced | 584 (26.9) | 549 (27.1) | 35 (24.0) | |
| Year of transplantation | .105 | |||
| 2000-2004 | 205 (9.4) | 184 (9.1) | 21 (14.4) | |
| 2005-2008 | 926 (42.6) | 868 (42.8) | 58 (39.7) | |
| 2009-2011 | 1041 (47.9) | 974 (48.1) | 67 (45.9) | |
| HLA matching | <.001 | |||
| 10/10 | 1379 (63.5) | 1325 (65.4) | 54 (37.0) | |
| 9/10 | 636 (29.3) | 571 (28.2) | 65 (44.5) | |
| 8/10 | 157 (7.2) | 130 (6.4) | 27 (18.5) | |
| Conditioning regimen | .618 | |||
| RIC | 838 (38.6) | 785 (38.7) | 53 (36.3) | |
| MAC | 1334 (61.4) | 1241 (61.3) | 93 (63.7) | |
| Graft source | 1.000 | |||
| BM | 123 (5.7) | 115 (5.7) | 8 (5.5) | |
| Peripheral blood stem cells | 2049 (94.3) | 1911 (94.3) | 138 (94.5) | |
| ATG treatment | .254 | |||
| Yes | 1194 (55.0) | 1123 (55.4) | 71 (48.6) | |
| No | 609 (28.0) | 564 (27.8) | 45 (30.8) | |
| Data missing | 369 (17.0) | 339 (16.7) | 30 (20.5) | |
| KPS | .016 | |||
| 80-100 | 1501 (69.1) | 1412 (69.7) | 89 (61.0) | |
| <80 | 102 (4.7) | 89 (4.4) | 13 (8.9) | |
| Data missing | 569 (26.2) | 525 (25.9) | 44 (30.1) | |
| Patient–donor CMV status combination | .097 | |||
| neg neg | 582 (26.8) | 550 (27.1) | 32 (21.9) | |
| neg pos | 184 (8.5) | 166 (8.2) | 18 (12.3) | |
| pos neg | 496 (22.8) | 460 (22.7) | 36 (24.7) | |
| pos | 559 (25.7) | 529 (26.1) | 30 (20.5) | |
| Data missing | 351 (16.2) | 321 (15.8) | 30 (20.5) | |
| Sex match | .494 | |||
| Other | 1906 (87.8) | 1781 (87.9) | 125 (85.6) | |
| Male patient-female donor | 266 (12.2) | 245 (12.1) | 21 (14.4) |
| Category . | Total . | MICA-129 matched . | MICA-129 mismatched . | P value . |
|---|---|---|---|---|
| Age | .258 | |||
| Median | 54 | 54 | 53.5 | |
| Range | 18-76 | 18-76 | 18-75 | |
| Diagnosis | .777 | |||
| AML | 808 (37.2) | 757 (37.4) | 51 (34.9) | |
| MDS | 552 (25.4) | 511 (25.2) | 41 (28.1) | |
| NHL | 339 (15.6) | 314 (15.5) | 25 (17.1) | |
| ALL | 309 (14.2) | 288 (14.2) | 21 (14.4) | |
| Acute leukemia | 164 (7.6) | 156 (7.7) | 8 (5.5) | |
| Disease stage | .513 | |||
| Early | 958 (44.1) | 895 (44.2) | 63 (43.2) | |
| Intermediate | 630 (29.0) | 582 (28.7) | 48 (32.9) | |
| Advanced | 584 (26.9) | 549 (27.1) | 35 (24.0) | |
| Year of transplantation | .105 | |||
| 2000-2004 | 205 (9.4) | 184 (9.1) | 21 (14.4) | |
| 2005-2008 | 926 (42.6) | 868 (42.8) | 58 (39.7) | |
| 2009-2011 | 1041 (47.9) | 974 (48.1) | 67 (45.9) | |
| HLA matching | <.001 | |||
| 10/10 | 1379 (63.5) | 1325 (65.4) | 54 (37.0) | |
| 9/10 | 636 (29.3) | 571 (28.2) | 65 (44.5) | |
| 8/10 | 157 (7.2) | 130 (6.4) | 27 (18.5) | |
| Conditioning regimen | .618 | |||
| RIC | 838 (38.6) | 785 (38.7) | 53 (36.3) | |
| MAC | 1334 (61.4) | 1241 (61.3) | 93 (63.7) | |
| Graft source | 1.000 | |||
| BM | 123 (5.7) | 115 (5.7) | 8 (5.5) | |
| Peripheral blood stem cells | 2049 (94.3) | 1911 (94.3) | 138 (94.5) | |
| ATG treatment | .254 | |||
| Yes | 1194 (55.0) | 1123 (55.4) | 71 (48.6) | |
| No | 609 (28.0) | 564 (27.8) | 45 (30.8) | |
| Data missing | 369 (17.0) | 339 (16.7) | 30 (20.5) | |
| KPS | .016 | |||
| 80-100 | 1501 (69.1) | 1412 (69.7) | 89 (61.0) | |
| <80 | 102 (4.7) | 89 (4.4) | 13 (8.9) | |
| Data missing | 569 (26.2) | 525 (25.9) | 44 (30.1) | |
| Patient–donor CMV status combination | .097 | |||
| neg neg | 582 (26.8) | 550 (27.1) | 32 (21.9) | |
| neg pos | 184 (8.5) | 166 (8.2) | 18 (12.3) | |
| pos neg | 496 (22.8) | 460 (22.7) | 36 (24.7) | |
| pos | 559 (25.7) | 529 (26.1) | 30 (20.5) | |
| Data missing | 351 (16.2) | 321 (15.8) | 30 (20.5) | |
| Sex match | .494 | |||
| Other | 1906 (87.8) | 1781 (87.9) | 125 (85.6) | |
| Male patient-female donor | 266 (12.2) | 245 (12.1) | 21 (14.4) |
Acute leukemia, acute leukemia not specified as AML or ALL (undifferentiated, biphenotypic, or secondary acute); ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; CMV, cytomegalovirus; KPS, Karnofsky performance score; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; neg, negative; NHL, non-Hodgkin lymphoma; pos, positive; RIC, reduced intensity conditioning.